Matinas BioPharma to Hold Virtual R&D Day on June 17, 2021
May 20 2021 - 8:00AM
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a
biopharmaceutical company focused on improving the intracellular
delivery of critical therapeutics through its paradigm-changing
lipid nanocrystal (LNC) delivery platform, today announced it will
host a virtual R&D Day on Thursday, June 17, beginning at 8:30
a.m. During the event, members of the Matinas management team will
discuss the Company’s key pipeline programs and its proprietary,
highly differentiated technology that solves complex challenges
relating to the safe and effective intracellular delivery of both
small and large molecules. In addition, two internationally
regarded clinical key opinion leaders will provide their
perspectives.
Pre-registration for the webcast is available
HERE and on the Investors section of the Company’s website at
www.matinasbiopharma.com. An interactive online Q&A session
with the presenters will be available during the event. Questions
can also be submitted via email to brandon.weiner@westwicke.com in
advance and prior to the event, or during the event itself.
R&D Day Information
Date: Thursday, June 17, 2021Time: 8:30 a.m. –
10:15 a.m. ET
Presenters
- David
R. Boulware, M.D., MPH, Professor of Medicine, Infectious
Disease & International Medicine, Department of Medicine,
University of Minnesota
- Peter
G. Pappas, M.D., Professor of Medicine,
Medicine/Infectious Diseases Department, University of Alabama at
Birmingham
- Jerome
D. Jabbour, Chief Executive Officer, Matinas
BioPharma
- James
J. Ferguson, M.D., FACC, FAHA, Chief Medical Officer,
Matinas BioPharma
- Theresa
Matkovits, Ph.D., Chief Development Officer, Matinas
BioPharma
- Raphael
J. Mannino, Ph.D., Chief Scientific Officer, Matinas
BioPharma
- Hui
Liu, Ph.D., Chief Technology Officer, Matinas
BioPharma
A live webcast of the R&D Day can be
accessed through the Investors section of the Company’s
website (www.matinasbiopharma.com). Please log in approximately 10
minutes prior to the scheduled start time. An archived webcast
replay will be made available on the Company’s website.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company
focused on improving the intracellular delivery of critical
therapeutics through its paradigm-changing lipid nanocrystal (LNC)
delivery platform. Company leadership has a deep history and
knowledge of drug development and is supported by a world-class
team of scientific advisors.
Matinas is developing a portfolio of products
based upon its proprietary LNC drug delivery platform, which can
solve complex challenges relating to the safe and effective
intracellular delivery of both small and larger, more complex
molecules.
MAT2203 is an oral, LNC formulation of the
well-known, but highly toxic, antifungal medicine amphotericin B,
primarily used to treat serious invasive fungal infections. MAT2203
is currently in a Phase 2 open-label, sequential randomized trial
(EnACT) in HIV-infected patients with cryptococcal meningitis.
EnACT is currently enrolling patients in its second cohort, with
the next DSMB evaluation of safety and efficacy data anticipated to
occur in the third quarter of 2021.
MAT2501 is an oral, LNC formulation of the
broad-spectrum aminoglycoside antibiotic medicine amikacin,
primarily used to treat chronic and acute bacterial infections. The
Company has been awarded up to $3.75 million from the Cystic
Fibrosis Foundation (CFF) to support development of MAT2501 toward
an indication to treat nontuberculous mycobacterial (NTM) lung
disease, including infections in patients with cystic fibrosis
(CF).
LYPDISO™, the Company’s product candidate
intended for the treatment of cardiovascular and metabolic
conditions, is a prescription-only omega-3 fatty acid-based
composition, comprised primarily of EPA and DPA. Matinas recently
announced data from the ENHANCE-IT study, a head-to-head crossover
study evaluating LYPDISO vs. Vascepa in patients with elevated
triglycerides. These data demonstrated superior levels of
eicosapentaenoic acid (EPA) in the blood with LYPDISO, and support
the potential superior cardioprotective effect of LYPDISO vs.
Vascepa. The Company has initiated a process to identity and secure
a potential partner to continue development of LYPDISO toward a
cardiovascular outcomes indication.
Forward-Looking Statements
This release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including those relating to the LNC platform
delivery technology, the Company’s strategic focus and the future
development of its product candidates, including MAT2203, MAT2501
and LYPDISO, the anticipated timing of regulatory submissions, the
anticipated timing of clinical studies, the anticipated timing of
regulatory interactions, the Company’s ability to identify and
pursue development and partnership opportunities for its products
or platform delivery technology on favorable terms, if at all, and
the ability to obtain required regulatory approval and other
statements that are predictive in nature, that depend upon or refer
to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to obtain additional capital to meet our liquidity needs on
acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials of our product
candidates; our ability to successfully complete research and
further development and commercialization of our product
candidates; the uncertainties inherent in clinical testing; the
timing, cost and uncertainty of obtaining regulatory approvals; our
ability to protect the Company’s intellectual property; the loss of
any executive officers or key personnel or consultants;
competition; changes in the regulatory landscape or the imposition
of regulations that affect the Company’s products; and the other
factors listed under "Risk Factors" in our filings with the SEC,
including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this release. Except as may be
required by law, the Company does not undertake any obligation to
release publicly any revisions to such forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. Matinas BioPharma’s
product candidates are all in a development stage and are not
available for sale or use.
Investor and Media ContactsPeter
VozzoWestwicke/ICR443-213-0505peter.vozzo@westwicke.com |
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Sep 2023 to Sep 2024